51 Results for "

mesothelioma

" in MedChemExpress (MCE) Product Catalog:
Products (51)

51 Results for "mesothelioma" in MCE Product Catalog:

34
34 Publications Verification
Cat. No.: HY-138565
CAS No.: 2563855-03-6
Purity:  99.89%
Target:  

YAP

Research Areas:  

Cancer

K-975 is a potent, selective and orally active TEAD inhibitor, with a strong inhibitory effect against protein-protein interactions between YAP1/TAZ and TEAD. K-975 covalently binds to Cys359 located in the palmitate-binding pocket of TEAD via an acrylamide structure. K-975 exhibits antitumor activity on malignant pleural mesothelioma .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-101255
CAS No.: 41443-28-1
Purity:  99.75%
Research Areas:  

Cancer

ODQ is a potent and selective soluble guanylyl cyclase (sGC, nitric oxide-activated enzyme) inhibitor. ODQ enhances the pro-apoptotic effects of Cisplatin in human mesothelioma cells .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-134957
CAS No.: 2417718-63-7
Purity:  99.89%
Target:  

YAP

Research Areas:  

Cancer

VT-107, as an analogous to VT104, is an orally active and potent pan-TEAD auto-palmitoylation inhibitor. VT-107 can be used for the research of cancer .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-153811
CAS No.: 2714434-21-4
Purity:  99.81%
Synonyms: YAP-TEAD-IN-3
Target:  

YAP Apoptosis

Research Areas:  

Cancer

IAG933 (YAP-TEAD-IN-3) is an orally available YAP/TAZ-TEAD inhibitor that has anti-tumor effects and promotes apoptosis. IAG933 YAP-TEAD-IN-3 inhibits Avi-human TEAD 4217-434, with an IC50 value of 9 nM .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-147135
CAS No.: 2416418-11-4
Purity:  98.48%
Synonyms: TEAD-IN-3
Target:  

YAP Apoptosis

Research Areas:  

Cancer

MYF-03-69 (TEAD-IN-3) is a covalent and irreversible TEAD inhibitor with IC50s of 385, 143, 558 and 173 nM for TEAD1, TEAD2, TEAD3 and TEAD4. MYF-03-69 disrupts YAP-TEAD association, suppresses TEAD transcriptional activity (IC50 = 56 nM) and up-regulates apoptosis gene BMF. MYF-03-69 selectively inhibits mesothelioma cancer cells with defective Hippo signaling. MYF-03-69 can be used for the study of malignant pleural mesothelioma (MPM) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-147136
CAS No.: 2857937-59-6
Purity:  99.52%
Target:  

YAP

Research Areas:  

Cancer

MYF-03-176 is an orally active inhibitor of TEAD, and suppresses TEAD transcriptional activity with an IC50 of 11 nM. The IC50 values of MYF-03-176 for TEAD1, TEAD3, and TEAD4 are 47, 32, and 71 nM, respectively. MYF-03-176 inhibits hippo signaling defective malignant pleural mesothelioma (MPM) cells. MYF-03-176 shows strong antitumor efficacy in MPM mouse xenograft model .
loading...
    loading...
Cat. No.: HY-400902
CAS No.: 2506273-81-8
Target:  

YAP VEGFR Hippo (MST)

Research Areas:  

Cancer

VT3989 is an orally active pan-TEAD autopalmitoylation inhibitor that modulates the Hippo signaling pathway. VT3989 directly binds to TEAD transcription factors to block their palmitoylation modification, thereby disrupting the formation of YAP/TAZ-TEAD complexes and inhibiting downstream oncogenic transcriptional activity. VT3989 effectively inhibits the growth of NF2-deficient schwannoma and meningioma cells and reverses the Schwann cell phenotype. In addition, VT3989 exerts a synergistic effect when combined with Osimtinib (HY-15772) in EGFR-mutant non-small cell lung cancer models, significantly delaying tumor recurrence and prolonging survival. VT3989 can be used for the research of epithelioid hemangioendothelioma, malignant pleural mesothelioma, type 2 neurofibromatosis and related advanced solid tumors .
loading...
    loading...
Cat. No.: HY-P99299
CAS No.: 845816-02-6
Synonyms: HGS-ETR 2; ETR2-ST01

Target:  

Apoptosis

Research Areas:  

Cancer

Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research .
loading...
    loading...
Cat. No.: HY-172113
Target:  

PROTACs YAP c-Myc Apoptosis

Research Areas:  

Cancer

H122 is a PROTAC degrader for TEAD that degrades TEAD1 with a DC50 of 3 nM. H122 exhibits good affinity to TEAD2, TEAD3, and TEAD4 with Ki values of 2.0, 3.6 and 1.6 nM, respectively. H122 relies on binding to TEAD1 and CRBN, functional E3 ligase activity, and a functional proteasome for degradation.H122 induces degradation of TEAD3 and forms a ternary complex with TEAD4 and CRBN/DDB1 to mediate degradation.H122 downregulates expression of Myc target genes. H122 exhibits antitumor efficacy in MSTO-211H mouse xenograft models.H122 can be used for the research of malignant mesothelioma .
loading...
    loading...
Cat. No.: HY-168016
CAS No.: 3058483-58-9
Target:  

PROTACs YAP

Research Areas:  

Cancer

PROTAC YAP degrader-1 is a VHL-recruiting PROTAC degrader (DC50=8.2 μM) and antiproliferative agent that targets YAP. PROTAC YAP degrader-1 recruits the E3 ligase VHL and binds to VHL to form a ternary complex containing YAP. PROTAC YAP degrader-1 inhibits the nuclear localization of YAP in cancer cells, reduces YAP/TEAD-mediated transcription, and induces TAZ protein degradation. PROTAC YAP degrader-1 reduces the oncogenic activity of YAP and exerts antiproliferative effects in the Huh7 xenograft mouse model. PROTAC YAP degrader-1 can be used for the research of hepatocellular carcinoma and mesothelioma .
loading...
    loading...
Cat. No.: HY-175357
CAS No.: 2957895-40-6
Target:  

YAP

Research Areas:  

Cancer

YAP/TEAD-IN-2 (Compound T-1) is a YAP/TEAD inhibitor. YAP/TEAD-IN-2 inhibits the luciferase activity driven by YAP/TEAD in 293T cells. YAP/TEAD-IN-2 exhibits strong anti-proliferative activity against human pleural mesothelioma NCI-H226 cells. YAP/TEAD-IN-2 can be used for the study of diseases associated with Hippo pathway dysregulation, particularly cancers .
loading...
    loading...
Cat. No.: HY-155163
CAS No.: 2196186-84-0
Purity:  98.93%
APG-2449 is an orally active inhibitor for BCL-2 and multikinase (ALK/FAK/ROS1) with potent antitumor activities. APG-2449 reduces cell viability and enhances apoptosis in acute myeloid leukemia cells in vitro. APG-2449 decreases activation of FAK and its downstream effectors. APG-2449 can be studied in research for mesothelioma tumor, non-small cell lung cancer, ovarian cancer, hematologic and solid malignancies .
loading...
    loading...
Cat. No.: HY-W009776
CAS No.: 38937-66-5
Synonyms: Suberohydroxamic acid; SBHA
Target:  

HDAC Apoptosis

Research Areas:  

Cancer

Suberoyl bis-hydroxamic acid (Suberohydroxamic acid; SBHA) is a competitive and cell-permeable HDAC1 and HDAC3 inhibitor with ID50 values of 0.25 μM and 0.30 μM, respectively .Suberoyl bis-hydroxamic acid renders MM cells susceptible to apoptosis and facilitates the mitochondrial apoptotic pathways .Suberoyl bis-hydroxamic acid can be used for the study of medullary thyroid carcinoma (MTC) .
loading...
    loading...
Cat. No.: HY-W007317
CAS No.: 578-66-5
8-Aminoquinoline is a chelating ligand and intermediate. 8-Aminoquinoline assists metal-catalyzed direct C (sp 2)-H and unactivated C (sp 3)-H bond functionalization, copper-mediated C-H/C-H coupling, as well as copper/silver-catalyzed aryl C (sp 2)-H amination reactions. 8-Aminoquinoline forms cationic Pt (II) complexes with anti-tumor activity. 8-Aminoquinoline is used in research related to latent malaria, glioblastoma, pancreatic adenocarcinoma, adenocarcinoma and biphasic mesothelioma .
loading...
    loading...
Cat. No.: HY-163644
CAS No.: 2417718-38-6
Target:  

YAP

Research Areas:  

Cancer

VT-105 is a TEAD inhibitor and VT104 (HY-134956) analog. VT-105 binds to the central hydrophobic pocket of the TEAD3 protein. VT-105 can be used in the research of NF2-deficient malignant mesothelioma .
loading...
    loading...
Cat. No.: HY-143411
CAS No.: 2487526-28-1
Research Areas:  

Cancer

GEM144 is a potent and orally active DNA polymerase α (POLA1) and HDAC 11 dual inhibitor. GEM144 induces acetylation of p53, activation of p21, G1/S cell cycle arrest, and apoptosis. GEM144 has significant antitumor activity in human orthotopic malignant pleural mesothelioma xenografts .
loading...
    loading...
Cat. No.: HY-P991551
CAS No.: 1656248-21-3

Research Areas:  

Infection Cancer

YS110 is a humanized anti-CD26 (DPP4) IgG1 monoclonal antibody. YS110 induces CD26 nuclear translocation through the caveolin pathway. YS110 inhibits the proliferation of tumor cell by delaying G2/M cell cycle transition. YS110 inhibits the infection of Middle East respiratory syndrome coronavirus (MERS CoV) by blocking the binding of MERS CoV S1 to CD26. YS110 can be used for researches on cancer or infection such as Malignant Mesothelioma and MERS .
loading...
    loading...
Cat. No.: HY-157673
CAS No.: 61599-23-3
Synonyms: 16:1 PE
Target:  

Phosphatase Apoptosis

Research Areas:  

Cancer

1,2-Dipalmitoleoyl-sn-glycero-3-phosphoethanolamine (16:1 PE) is a phosphatidylethanolamine that can enhance PP2A and PTP1B activities in malignant pleural mesothelioma cells. 1,2-Dipalmitoleoyl-sn-glycero-3-phosphoethanolamine induces apoptosis of NCI-H28 malignant pleural mesothelioma cells .
loading...
    loading...
Cat. No.: HY-179395
CAS No.: 3074990-47-6
Target:  

YAP

Research Areas:  

Cancer

TEAD-IN-23 (Compound 22) is an efficient pan-TEAD inhibitor with an IC50 of 10 nM. TEAD-IN-23 exhibits potent anti-proliferative activity in both NCI-H226 and MSTO-211H. TEAD-IN-23 causes complete tumor regression in the MSTO-211H xenograft tumor model. TEAD-IN-23 can be used for the study of mesothelioma and hepatocellular carcinoma .
loading...
    loading...
Cat. No.: HY-171450
CAS No.: 1802770-18-8
Target:  

Trk Receptor

Research Areas:  

Cancer

VMD-928 is an orally active, allosteric, irreversible and selective tropomyosin receptor kinase A (TrkA) inhibitor. VMD-928 blocks the downstream signaling pathways triggered by the binding of nerve growth factor (NGF) to TrkA, thereby inhibiting cell proliferation, invasion, and promoting cancer cell death. VMD-928 is promising for research of various cancers, including prostate cancer, thymic carcinoma, mesothelioma, squamous cell carcinoma of the head and neck, squamous cell carcinoma of the lung, ovarian cancer, hepatocellular carcinoma .
loading...
    loading...